Critical Analysis of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Inhibitors and Potential Role of Zalunfiban, a Novel Small Molecule Glycoprotein Inhibitor, in Understanding the Mechanism(s) [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023 Thrombocytopenia is a rare but serious complication of the intravenous glycoprotein IIb/IIIa (GPIIb/IIIa; integrin αIIbβ3) receptor inhibitors (GPIs), abciximab, eptifibatide, and tirofiban. The thrombocytopenia ranges from mild (50 000–100 000 platelets/
Sem A. O. F. Rikken +4 more
doaj +2 more sources
Abciximab-Associated Pseudothrombocytopenia [PDF]
Circulation, 2000 A60-year-old woman was transferred for coronary angiography after a non–Q-wave myocardial infarction. She was treated with aspirin, metoprolol, unfractionated heparin, and abciximab administered as a weight-based bolus followed by infusion. A complete blood count in blood anticoagulated with EDTA (purple-top Vacutainer) was obtained shortly after her ...
Michael B. Holmes +4 more
openalex +4 more sources
Effects of abciximab on key pattern of human coronary restenosis in vitro: impact of the SI/MPL-ratio [PDF]
BMC Cardiovascular Disorders, 2006 Background The significant reduction of angiographic restenosis rates in the ISAR-SWEET study (intracoronary stenting and antithrombotic regimen: is abciximab a superior way to eliminate elevated thrombotic risk in diabetes) raises the question of ...
Baur Regine +4 more
doaj +4 more sources
Alveolar Hemorrhage during Abciximab Infusion
Journal of Tehran University Heart Center, 2021 Not ...
Yavuzer Koza +3 more
doaj +5 more sources
Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration [PDF]
Trials, 2009 Background Administration of abciximab during primary percutaneous coronary intervention is an effective adjunctive therapy in the treatment of patients with ST-segment elevation myocardial infarction.
Gu Youlan L +6 more
doaj +6 more sources
Early recovery of microvascular perfusion induced by t-PA in combination with abciximab or eptifibatide during postischemic reperfusion [PDF]
, 2002 BACKGROUND: GPIIb/IIIa inhibitors abciximab and eptifibatide have been shown to inhibit platelet aggregation in ischemic heart disease. Our aim was to test the efficacy of abiciximab (Reo Pro) or eptifibatide (Integrilin) alone or in combination with ...
Bertuglia, Silva, Giusti, Andrea
core +4 more sources
Elective or selective use of abciximab? [PDF]
The Lancet, 2000 38965
Robert J. Butler, NJ Samani
openalex +5 more sources
Abciximab-induced thrombocytopenia [PDF]
QJM, 2002 Sir, Abciximab is a potent platelet glycoprotein IIb/IIIa receptor antagonist, currently indicated as adjunctive therapy during percutaneous coronary intervention and acute coronary syndromes. Potential future indications include acute myocardial infarction, peripheral arterial disease and ischaemic stroke, thus more widespread use is likely in the ...
C. Griffiths
openalex +3 more sources
Efficacy and safety of abciximab in diabetic patients who underwent percutaneous coronary intervention with thienopyridines loading: a meta-analysis. [PDF]
PLoS ONE, 2011 BACKGROUND: It has been controversial whether abciximab offered additional benefits for diabetic patients who underwent percutaneous coronary intervention (PCI) with thienopyridines loading.
Yihua Wu +6 more
doaj +5 more sources
Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials [PDF]
Journal of Interventional Cardiology, 2022 Objectives. This meta-analysis was to verify the short-time efficacy and safety of abciximab in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). Background.
Nan Bai +5 more
doaj +2 more sources